

Special Issue

Gastric Cancer: From Pathophysiologic Mechanisms to Therapeutic Strategies

Message from the Guest Editors

Despite the substantial progress made in our understanding of the causes, pathogenesis, diagnosis, and treatment of gastric cancer in the past few decades, this disease remains one of the leading causes of cancer death. The identification and validation of new and effective biomarkers and drug targets are needed for patients with gastric cancer. Recently, cutting-edge omics technologies, such as spatiotemporal omics and single-cell omics, have emerged, changing cancer research and treatment. These tools could help make significant progress in exploring the tumor microenvironment, cancer cell evolution and interaction with immune and stromal cells, etc., and identifying more specific and promising biomarkers and targets for human cancer, including gastric cancer. We invite authors to submit original research and review articles that focus on basic and translational research on gastric cancer with various new and powerful technologies. The goal is to stimulate research and clinical interest in developing strategies for the prediction, prevention, diagnosis, and treatment of gastric cancer to finally improve the treatment outcomes in patients with this malignant disease.

Guest Editors

Dr. Jiang-Jiang Qin

Institute of Basic Medicine and Cancer, Chinese Academy of Sciences (CAS), Hangzhou, China

Dr. Xiaoqing Guan

Zhejiang Cancer Hospital, Hangzhou, China

Deadline for manuscript submissions

closed (30 June 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/172211

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).